Metabolic dysfunction, obesity, and survival among patients with early-stage colorectal cancer

Journal of Clinical Oncology

Volumn 34, Issue 30, 2016, Pages 3664-3671

  Feliciano, Elizabeth M Cespedes ^a   Kroenke, Candyce H ^a   Meyerhardt, Jeffrey A ^c   Prado, Carla M ^d   Bradshaw, Patrick T ^b   Dannenberg, Andrew J ^e   Kwan, Marilyn L ^a   Xiao, Jingjie ^d   Quesenberry, Charles ^a   Weltzien, Erin K ^a   Castillo, Adrienne L ^a   Caan, Bette J ^a  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EARLY CANCER; ELEVATED BLOOD PRESSURE; FEMALE; FOLLOW UP; HUMAN; INTRAPERITONEAL FAT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MIDDLE AGED; MUSCLE MASS; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 84992437292     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.4473     Document Type: Article

References (54)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66:7-30, 2016
2. Sinicrope FA, Foster NR, Yothers G, et al: Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer 119:1528-1536, 2013
3. Kroenke CH, Neugebauer R, Meyerhardt J, et al: Analysis of body mass index and mortality in patients with colorectal cancer using causal diagrams. JAMA Oncol 10.1001/jamaoncol.2016.0732 [epub ahead of print on May 19, 2016
4. Baade PD, Meng X, Youl PH, et al: The impact of body mass index and physical activity on mortality among patients with colorectal cancer in Queensland, Australia. Cancer Epidemiol Biomarkers Prev 20:1410-1420, 2011
5. Campbell PT, Newton CC, Dehal AN, et al: Impact of body mass index on survival after colorectal cancer diagnosis: The Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 30:42-52, 2012
6. Kuiper JG, Phipps AI, Neuhouser ML, et al: Recreational physical activity, body mass index, and survival in women with colorectal cancer. Cancer Causes Control 23:1939-1948, 2012
7. Meyerhardt JA, Niedzwiecki D, Hollis D, et al: Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: Findings from Cancer and Leukemia Group B 89803. J Clin Oncol 26:4109-4115, 2008
8. Schlesinger S, Siegert S, Koch M, et al: Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: A prospective study and meta-analysis. Cancer Causes Control 25:1407-1418, 2014
9. Moore LL, Chadid S, Singer MR, et al: Metabolic health reduces risk of obesity-related cancer in Framingham Study adults. Cancer Epidemiol Biomarkers Prev 23:2057-2065, 2014
10. Khandekar MJ, Cohen P, Spiegelman BM: Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 11:886-895, 2011
11. Azvolinsky A: Cancer prognosis: Role of BMI and fat tissue. J Natl Cancer Inst 106: dju177, 2014
12. Grundy SM, Brewer HB Jr, Cleeman JI, et al: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433-438, 2004
13. Trevisan M, Liu J, Bahsas FB, et al: Syndrome X and mortality: A population-based study. Am J Epidemiol 148:958-966, 1998
14. Oh C-M, Jun. JK, Suh M: Risk of cancer mortality according to the metabolic health status and degree of obesity. Asian Pac J Cancer Prev 15:10027-10031, 2014
15. Lee JS, Cho SI, Park HS: Metabolic syndrome and cancer-related mortality among Korean men and women. Ann Oncol 21:640-645, 2010
16. Jaggers JR, Sui X, Hooker SP, et al: Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer 45:1831-1838, 2009
17. Esposito K, Chiodini P, Capuano A, et al: Colorectal cancer association with metabolic syndrome and its components: A systematic review with metaanalysis. Endocrine 44:634-647, 2013
18. Colangelo LA, Gapstur SM, Gann PH, et al: Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 11:385-391, 2002
19. Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA, et al: Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol 34:1339-1344, 2016
20. van Vledder MG, Levolger S, Ayez N, et al: Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 99:550-557, 2012
21. Miyamoto Y, Baba Y, Sakamoto Y, et al: Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann Surg Oncol 22:2663-2668, 2015
22. Prado C, Cushen S, Orsso C, et al: Sarcopenia and cachexia in the era of obesity: Clinical and nutritional impact. Proc Nutr Soc: 75:188-198, 2016
23. Shen W, Punyanitya M, Wang Z, et al: Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 97:2333-2338, 2004
24. Mourtzakis M, Prado CM, Lieffers JR, et al: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33:997-1006, 2008
25. Prado CM, Birdsell LA, Baracos VE: The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 3:269-275, 2009
26. Grundy SM, Cleeman JI, Daniels SR, et al: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 13:322-327, 2005
27. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
28. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
29. Kohl M, Heinz G: PSHREG: A SAS macro for proportional and nonproportional subdistribution hazards regression. Comput Methods Programs Biomed 118. 2:218-233, 2015
30. Lin G, So Y, Johnston G: Analyzing survival data with competing risks using SAS software. SAS Global Forum, 2012. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.306.7517&rep=rep1&type=pdf
31. Hsu WC, Araneta MRG, Kanaya AM, et al: BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care 38:150-158, 2015
32. WHO Expert Consultation: Appropriate bodymass index for Asian populations and its implications for policy and intervention strategies. Lancet 363:157-163, 2004
33. [Erratum: Lancet 363:902, 2004]
34. World Health Organization, International Association for the Study of Obesity, International Obesity Task Force: Assessment/diagnosis, in: The Asia-Pacific perspective: Redefining obesity and its treatment. Sydney, Australia. Health Communications Australia 2000, pp 15-21
35. Meyerhardt JA, Kroenke CH, Prado CM, et al: Association of weight change after colorectal cancer diagnosis and outcomes in the Kaiser Permanente Northern California Population. Cancer Epidemiol Biomarkers Prev (in press)
36. Lee J, Hong YP, Shin HJ, et al: Associations of sarcopenia and sarcopenic obesity with metabolic syndrome considering both muscle mass and muscle strength. J Prev Med Public Health 49:35-44, 2016
37. Prado CM, Gonzalez MC, Heymsfield SB: Body composition phenotypes and obesity paradox. Curr Opin Clin Nutr Metab Care 18:535-551, 2015
38. Gonzalez MC, Pastore CA, Orlandi SP, et al: Obesity paradox in cancer: New insights provided by body composition. Am J Clin Nutr 99:999-1005, 2014
39. Trevisan M, Liu J, Muti P, et al: Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 10:937-941, 2001
40. Perseghin G, Calori G, Lattuada G, et al: Insulin resistance/hyperinsulinemia and cancer mortality: The Cremona study at the 15th year of follow-up. Acta Diabetol 49:421-428, 2012
41. Gallagher EJ, LeRoith D: The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21:610-618, 2010
42. Renehan AG, Frystyk J, Flyvbjerg A: Obesity and cancer risk: The role of the insulin-IGF axis. Trends Endocrinol Metab 17:328-336, 2006
43. Yang Y, Mauldin PD, Ebeling M, et al: Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients. Cancer 119:1512-1520, 2013
44. Gallagher EJ, LeRoith D: Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care 36: S233-S239, 2013 (suppl 2)
45. Muc-Wierzgoń M, Nowakowska-Zajdel E, Dziȩgielewska-Gȩsiak S, et al: Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer. World J Gastroenterol 20:9759-9774, 2014
46. Mei ZB, Zhang ZJ, Liu CY, et al: Survival benefits of metformin for colorectal cancer patients with diabetes: A systematic review and metaanalysis. PLoS One 9: e91818, 2014
47. [Erratum: PLoS One 9: e103652, 2014]
48. Kalinsky K, Crew KD, Refice S, et al: Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest 32:150-157, 2014
49. Kim J, Lim W, Kim EK, et al: Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). BMC Cancer 14:170, 2014
50. Ko KP, Ma SH, Yang JJ, et al: Metformin intervention in obese non-diabetic patients with breast cancer: Phase II randomized, double-blind, placebocontrolled trial. Breast Cancer Res Treat 153:361-370, 2015
51. Boman BM, Bandos H, Wickerham DL, et al: Statin polyp prevention trial in patients with resected colon cancer: NSABP protocol P-5. J Clin Oncol 30, 2012 (suppl; abstr TPS1615)
52. Ling Y, Yang L, Huang H, et al: Prognostic significance of statin use in colorectal cancer: A systematic review and meta-analysis. Medicine (Baltimore) 94: e908, 2015
53. Zhong S, Zhang X, Chen L, et al: Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies. Cancer Treat Rev 41:554-567, 2015
54. Bell JA, Hamer M, Sabia S, et al: The natural course of healthy obesity over 20 years. J Am Coll Cardiol 65:101-102, 2015